Market closedNon-fractional
CureVac/CVAC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About CureVac
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
Ticker
CVAC
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Tübingen, Germany
Employees
1,086
Website
www.curevac.com
CureVac Metrics
BasicAdvanced
$816M
Market cap
-
P/E ratio
-$1.32
EPS
2.67
Beta
-
Dividend rate
Price and volume
Market cap
$816M
Beta
2.67
Financial strength
Current ratio
2.25
Quick ratio
2.014
Long term debt to equity
7.955
Total debt to equity
9.094
Management effectiveness
Return on assets (TTM)
-21.53%
Return on equity (TTM)
-47.11%
Valuation
Price to revenue (TTM)
12.729
Price to book
1.83
Price to tangible book (TTM)
1.97
Price to free cash flow (TTM)
-2.407
Growth
Revenue change (TTM)
17.59%
Earnings per share change (TTM)
-18.28%
3-year revenue growth (CAGR)
1.89%
3-year earnings per share growth (CAGR)
-0.27%
What the Analysts think about CureVac
Analyst Ratings
Majority rating from 9 analysts.
CureVac Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
€12M
-45.33%
Net income
-€71M
-18.59%
Profit margin
-573.17%
48.92%
CureVac Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-€0.30
-€0.22
-€0.39
-€0.31
-
Expected
-€0.24
-€0.23
-€0.19
-€0.23
-€0.24
Surprise
25.00%
-3.51%
110.81%
35.96%
-
CureVac News
AllArticlesVideos
CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech
Accesswire·2 weeks ago
GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines
Barrons·3 weeks ago
CureVac's stock soars on GSK's $1.56 billion deal for its COVID-19 and flu vaccines
Market Watch·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CureVac stock?
CureVac (CVAC) has a market cap of $816M as of July 27, 2024.
What is the P/E ratio for CureVac stock?
The price to earnings (P/E) ratio for CureVac (CVAC) stock is 0 as of July 27, 2024.
Does CureVac stock pay dividends?
No, CureVac (CVAC) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next CureVac dividend payment date?
CureVac (CVAC) stock does not pay dividends to its shareholders.
What is the beta indicator for CureVac?
CureVac (CVAC) has a beta rating of 2.67. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell CureVac stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.